Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite Inc. is offering 696,866 shares of common stock at an offering price of $1.435 per share pursuant to this prospectus supplement, with expected gross proceeds of approximately $1.0 million. The offering is being conducted with H.C. Wainwright & Co. as exclusive placement agent and closes subject to customary conditions.
Concurrently, Amesite is conducting a private placement of Pre-Funded Warrants and two series of unregistered common stock warrants (Series A-1 and Series A-2) to the purchasers under the Securities Purchase Agreement dated April 27, 2026. Certain directors (including the CEO) are participating in the Private Placement on the same economic terms, and the Audit Committee and Board approved those related-party investments.
Amesite Inc. is offering 696,866 shares of common stock at an offering price of $1.435 per share pursuant to this prospectus supplement, with expected gross proceeds of approximately $1.0 million. The offering is being conducted with H.C. Wainwright & Co. as exclusive placement agent and closes subject to customary conditions.
Concurrently, Amesite is conducting a private placement of Pre-Funded Warrants and two series of unregistered common stock warrants (Series A-1 and Series A-2) to the purchasers under the Securities Purchase Agreement dated April 27, 2026. Certain directors (including the CEO) are participating in the Private Placement on the same economic terms, and the Audit Committee and Board approved those related-party investments.
Amesite Inc. furnished updated shareholder presentation materials outlining progress of its AI-driven NurseMagic platform and broader business. The update highlights large non-acute care markets across home care, home health, hospice, senior living and skilled nursing, and describes disruptive documentation and EMR pricing starting around $1 per patient per month.
The materials note prior revenue momentum, including earlier periods with 240% and 63% revenue growth and Q2 2026 revenues of $108,050, along with a mix of B2C and B2B customers. Amesite also emphasizes having zero corporate debt, several months of operating cash coverage, growing social media reach for NurseMagic, and a sales pipeline of multi-site healthcare organizations.
Amesite Inc. is registering 2,777,778 shares of common stock with accompanying warrants, plus related pre-funded warrants and underlying shares, in a primary public offering. The assumed combined price is $1.80 per share and warrant, with estimated net proceeds of about $4.47 million for working capital and general corporate purposes.
Each accompanying warrant has a $1.80 exercise price, is immediately exercisable, and expires five years after issuance. Investors that would exceed 4.99% (or 9.99% at their election) ownership may receive pre-funded warrants with a $0.001 exercise price instead of common stock. Shares outstanding are expected to increase from 4,572,713 to 7,350,491, excluding the underwriters’ 416,667-share over-allotment option.
The company highlights substantial risks, including recurring net losses, substantial doubt about its ability to continue as a going concern, intense competition in AI healthcare, heavy regulatory and cybersecurity demands, and the risk of Nasdaq delisting if it cannot regain and maintain stockholders’ equity compliance.
OMENN GILBERT S reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, received a grant of 6,522 restricted stock units on March 31, 2026. Each unit represents one share of Amesite common stock or its cash equivalent, awarded in lieu of cash director fees based on the quarter-end closing share price. The deferred stock units or cash equivalent will be delivered after he leaves the board or upon an earlier change in control. Following this award, the trust’s indirect holdings reported in this line total 74,783 shares.
Brewer Barbie reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Barbie Brewer received a grant of 7,541 restricted stock units. These RSUs were awarded as deferred stock units in lieu of cash fees for her board service, with the number of units based on the closing share price on the last day of the quarter.
Each RSU represents the right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after she completes service on the board or upon an earlier change in control. Following this grant, she holds 30,322 shares or equivalents directly.
Parmer George reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director George Parmer received a grant of 6,522 restricted stock units. These RSUs were issued as deferred stock units in lieu of cash compensation for his board service, with the number of units based on Amesite’s closing share price on the last day of the quarter.
Each RSU represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after Parmer’s board service ends or upon an earlier change in control. Following this award, he holds 67,887 shares or share-equivalent units directly.
LOSH J MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director J. Michael Losh had 7,880 restricted stock units credited to the J. Michael Losh Irrevocable Qualified Annuity Trust #7. These units were issued as deferred stock units in lieu of cash fees for board service and are tied to the closing share price on the last day of the quarter.
Each restricted stock unit represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after Mr. Losh’s service on the board ends or upon an earlier change in control. Following this grant, the trust is reported as holding 90,363 deferred/restricted stock units in total, all indirectly associated with Mr. Losh.
Amesite Inc. director Parmer George exercised restricted stock units into common shares, increasing his direct equity stake. On March 7, 2026, 41,322 restricted stock units converted into 41,322 shares of Amesite common stock at a stated price of $0.00 per share. Following the transaction, George directly owned 323,060 shares of common stock. The reported restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026, with each unit representing a right to receive one share of common stock or its cash equivalent. No open-market purchases or sales were reported in this filing.
Amesite Inc. director Barbie Brewer exercised restricted stock units that had vested into common shares. On March 7, 2026, she converted 41,322 restricted stock units into 41,322 shares of Amesite common stock at a stated price of $0.00 per share as part of her equity compensation.
These restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026. Following the conversion, Brewer directly holds 135,977 shares of Amesite common stock, and there are no remaining derivative positions from this RSU grant disclosed in the filing.